Kaplan-Meier survival estimate

4 downloads 0 Views 258KB Size Report
21 21 17 13 12 12 10 9 8 7 4 3 2 2 0. Government. 40 29 17 15 13 10 9 8 7 6 5 3 2 1 0. Internal. Number at risk. 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 analysis time ...
Fig A. Kaplan-Meier survival curve for the publication fate of the 80 included randomized trials.

0.00

0.25

0.50

0.75

1.00

Kaplan-Meier survival estimate

0 Number at risk

1

2

3

4

5 6 7 8 9 10 11 12 13 14 analysis time (years)

80 62 45 34 28 25 19 17 15 13

9

6

4

3

0

Fig B. Kaplan–Meier survival estimates for the lag between trial completion and publication according to registry.

0.00

0.25

0.50

0.75

1.00

Kaplan-Meier survival estimates

0

1

2

3

4

5 6 7 8 9 10 11 12 13 14 analysis time (years)

Number at risk ClinicalTrials.gov 45 29 16 11 8 5 3 3 2 2 ISRCTN 35 33 29 23 20 20 16 14 13 11 ClinicalTrials.gov

1 8

0 6

0 4

ISRCTN

0 3

0 0

0.00

0.25

0.50

0.75

1.00

Fig C. Kaplan–Meier survival estimates for the lag between trial completion and publication according to registration timing. Kaplan-Meier survival estimates

0

1

2

3

4

5 6 7 8 9 10 11 12 13 14 analysis time (years)

Number at risk Retrospective 61 49 37 30 24 22 17 15 13 11 Prospective 19 13 8 4 4 3 2 2 2 2 Retrospective

9 0

6 0

4 0

Prospective

3 0

0 0

0.00

0.25

0.50

0.75

1.00

Fig D. Kaplan–Meier survival estimates for the lag between trial completion and publication according to trial affiliation. Kaplan-Meier survival estimates

0

1

2

3

4

5

6 7 8 9 10 11 12 13 14 analysis time (years)

Number at risk University 63 47 32 24 19 16 12 10 Practice 1 0 0 0 0 0 0 0 Hospital 16 15 13 10 9 9 7 7 University Hospital

9 0 6

8 0 5

5 0 4

3 0 3

Practice

2 0 2

1 0 2

0 0 0

Fig E. Kaplan–Meier survival estimates for the lag between trial completion and publication according to geographic origin.

0.00 0.25 0.50 0.75 1.00

Kaplan-Meier survival estimates

0

1

2

3

4

5 6 7 8 9 10 11 12 13 14 analysis time (years)

Number at risk Europe 47 Asia 11 N. America 14 S. America/ Africa 8

40 5 10 7

34 1 6 4

27 1 3 3

22 1 2 3

21 0 2 2

17 0 1 1

15 0 1 1

Europe N. America

14 0 1 0

12 0 1 0

9 0 0 0

6 0 0 0

4 0 0 0

3 0 0 0

0 0 0 0

Asia S. America/Africa

0.00 0.25 0.50 0.75 1.00

Fig F. Kaplan–Meier survival estimates for the lag between trial completion and publication according to sponsor. Kaplan-Meier survival estimates

0

Number at risk Internal Government Commercial Other

1

2

3

4

5

6 7 8 9 10 11 12 13 14 analysis time (years)

40 29 17 15 13 10 9 21 21 17 13 12 12 10 10 6 5 3 1 1 0 9 6 6 3 2 2 0 Internal Commercial

8 9 0 0

7 8 0 0

6 7 0 0

5 4 0 0

3 3 0 0

2 2 0 0

Government Other

1 2 0 0

0 0 0 0

0.00

0.25

0.50

0.75

1.00

Fig G. Kaplan–Meier survival estimates for the lag between trial completion and publication according to number of trial centers. Kaplan-Meier survival estimates

0

1

2

3

4

5

6 7 8 9 10 11 12 13 14 analysis time (years)

Number at risk Singlecenter 74 56 40 30 26 23 18 17 15 13 Multicenter 6 6 5 4 2 2 1 0 0 0 Singlecenter

9 0

6 0

4 0

Multicenter

3 0

0 0

Fig H. Kaplan–Meier survival estimates for the lag between trial completion and publication according to trial size.

0.00

0.25

0.50

0.75

1.00

Kaplan-Meier survival estimates

0

1

2

3

4

5 6 7 8 9 10 11 12 13 14 analysis time (years)

Number at risk 66 48 32 23 17 14 10 9 Not large 5 5 4 3 3 3 1 0 Large Not large

8 0

6 0

3 0

3 0

Large

2 0

2 0

0 0

0.00 0.25 0.50 0.75 1.00

Fig I. Kaplan–Meier survival estimates for the lag between trial completion and publication according to eligible patients’ age. Kaplan-Meier survival estimates

0 Number at risk Children Adults Mixed Unclear

1

2

3

4

5

6 7 8 9 10 11 12 13 14 analysis time (years)

29 25 19 13 10 8 5 8 4 3 3 3 3 2 29 20 10 7 4 3 2 14 13 13 11 11 11 10 Children Mixed

4 2 2 9

4 2 1 8

3 2 1 7

1 1 1 6

1 1 0 4

Adults Unclear

1 1 0 2

1 0 0 2

0 0 0 0

0.00

0.25

0.50

0.75

1.00

Fig J. Kaplan–Meier survival estimates for the lag between trial completion and publication according to outcome type. Kaplan-Meier survival estimates

0

1

2

3

4

5 6 7 8 9 10 11 12 13 14 analysis time (years)

Number at risk Objective 73 57 40 29 23 21 16 15 13 11 Subjective 6 4 4 4 4 3 2 1 1 1 Objective

7 1

4 1

2 1

Subjective

2 0

0 0

0.00

0.25

0.50

0.75

1.00

Fig K. Kaplan–Meier survival estimates for the lag between trial completion and publication according to journal type. Kaplan-Meier survival estimates

0

1

2

3

4

5 6 7 8 9 10 11 12 13 14 analysis time (years)

Number at risk Non-specialty 12 6 2 Specialty 21 18 13

0 7

0 4

0 3

0 0

0 0

Non-specialty

0 0

0 0

0 0

0 0

0 0

Specialty

0 0

0 0

0.00

0.25

0.50

0.75

1.00

Fig L. Kaplan–Meier survival estimates for the lag between trial completion and publication according to journal type (electronic publishing). Kaplan-Meier survival estimates

0

1

2

3

4

5

Number at risk No epub 15 12 Epub 18 12

7 8

3 4

2 2

2 1

6 7 8 9 10 11 42 13 14 analysis time (years) 0 0

No epub

0 0

0 0

0 0

0 0 Epub

0 0

0 0

0 0

0 0

0.00

0.25

0.50

0.75

1.00

Fig M. Kaplan–Meier survival estimates for the lag between trial completion and publication according to their findings. Kaplan-Meier survival estimates

0

1

2

3

4

5 6 7 8 9 10 11 12 13 14 analysis time (years)

Number at risk Non-positive results 14 10 Positive results 15 10

8 4

4 1

2 1

1 1

0 0

0 0

Not positive

0 0

0 0

0 0

0 0

Positive

0 0

0 0

0 0

Fig N. Geographic content of the two assessed trial registries.

ISRCTN

ClinicalTrials. gov

19

1

1

2

2

3

4

18

5 6 7 8 9

17 10 16 3 1 3

Germany UK

2

Italy

1 3 5 7 9 11 13 15 17 19

11 15 14 13 12

Austria Brazil China Egypt Germany India Italy Sweden UK notgiven

2 4 6 8 10 12 14 16 18

Belgium Canada Colombia France Hong Kong Iran Kuwait Syria USA